Nuvectis Pharma, Inc.
NVCT
$9.24
$0.819.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.33% | 26.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.66% | 47.95% | |||
| Operating Income | 13.66% | -47.95% | |||
| Income Before Tax | 14.66% | -50.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.66% | -50.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.66% | -50.45% | |||
| EBIT | 13.66% | -47.95% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 23.99% | -45.98% | |||
| Normalized Basic EPS | 24.01% | -46.02% | |||
| EPS Diluted | 23.99% | -45.98% | |||
| Normalized Diluted EPS | 24.01% | -46.02% | |||
| Average Basic Shares Outstanding | 12.27% | 3.06% | |||
| Average Diluted Shares Outstanding | 12.27% | 3.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||